Cipla Ltd. (CIPL)

Currency in INR
1,411.00
+6.90(+0.49%)
Closed·
Advertisement
CIPLA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,382.001,411.00
52 wk Range
1,165.701,539.70
Key Statistics
Bid/Ask
1,410.00 / 1,411.00
Prev. Close
1,404.1
Open
1,387
Day's Range
1,382-1,411
52 wk Range
1,165.7-1,539.7
Volume
1.57M
Average Volume (3m)
990.65K
1-Year Change
-6.2894%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CIPLA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,507.31
Upside
+6.83%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Cipla Ltd. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

22 Buy
12 Hold
2 Sell
Ratings:
36 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,507.31
(+6.83% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Nomura/Instinet
Buy1,580.00+11.98%1,510.00Maintain28/10/2026
Jefferies
Hold1,270.00-9.99%1,170.00Upgrade28/10/2026
Macquarie
Buy1,730.00+22.61%1,675.00Maintain07/10/2026
Kotak
Buy1,675.00+18.71%1,660.00Maintain28/07/2026
JPMorgan
Buy1,600.00+13.39%1,550.00Maintain24/07/2026

Cipla Ltd. Earnings Call Summary for Q2/2027

  • Cipla Q2 FY2027 revenue rose 4% QoQ to INR 7,404 crores; EBITDA margin expanded 200bps to 18.7% on improved product mix and execution.
  • India business posted 12% YoY growth with branded prescriptions up 15%; company maintained No. 1 U.S. albuterol MDI position at 22% market share.
  • Management reaffirmed FY2027 EBITDA margin guidance of 18.5%-20% and $1B annualized North America revenue run rate target by year-end.
  • Shares fell 1.85% to $1,330 as investors weighed FDA approval timing risks and dependence on limited respiratory product launches for U.S. growth.
  • Company targets pembrolizumab biosimilar filing in 2028 for 2029 launch; Pithampur facility received 7 FDA observations requiring remediation.
Last Updated: 27/10/2026, 11:44
Read Full Transcript

Earnings

Latest Release
26/10/2026
EPS / Forecast
10.85 / 11.54
Revenue / Forecast
74.04B / 76.23B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 35.86
Dividend Yield
0.93%
Industry Median 0.66%
Annualised payout
13.00
Paid annually
5-Years Growth
+21.06%
Growth Streak

Cipla (CIPLA) Income Statement & Profits

Compare CIPLA to Peers and Sector

Metrics to compare
CIPLA
Peers
Sector
Relationship
P/E Ratio
39.3x30.2x−0.2x
PEG Ratio
−0.840.650.00
Price/Book
3.2x4.2x2.6x
Price / LTM Sales
4.1x4.1x2.8x
Upside (Analyst Target)
6.8%13.3%65.6%
Fair Value Upside
Unlock−1.7%10.0%Unlock

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Employees
31369
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
364.01M45.06%513.61B
Other Institutional Investors
18.99M2.35%26.80B
Public Companies & Retail Investors
424.89M52.59%599.51B
Total
807.89M100.00%1.14T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Life Insurance Corporation of India9.59%77,465,141109,303,314
LIC New Endowment Plus-Secured Fund9.59%77,465,141109,303,314

People Also Watch

2,745.80
ADEL
+0.46%
10,900.00
BAJA
+1.32%
5,000.00
TITN
+3.42%
1,373.00
REDY
+0.51%
1,320.00
RELI
+0.50%

FAQ

What Is the Cipla (NSE: CIPLA) Share Price Today?

The Cipla stock price today is 1,411.00 INR.

What Stock Exchange Does Cipla (CIPLA) Trade On?

Cipla is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Cipla?

The stock symbol (also called a 'ticker') for Cipla is "CIPLA."

Does Cipla Pay Dividends? What’s The Current CIPLA Dividend Yield?

Yes, CIPLA Pays Dividends to its Shareholders. The current Cipla dividend yield is 0.9%%.

What Is the Current Cipla Market Capitalisation?

As of today, Cipla (NSE: CIPLA) market cap is 1.14T INR.

What Is Cipla's (CIPLA) Earnings Per Share (TTM)?

The Cipla EPS is currently 35.86 (Trailing Twelve Months).

When Is the Next Cipla Earnings Date?

Cipla's next earnings report will be released on 22/01/2027.

Is CIPLA a Buy or Sell From a Technical Analyst Perspective?

Based on today's Cipla moving averages and other technical indicators, the daily buy/sell signal for CIPLA stock is Strong Buy.

How Many Times Has Cipla Stock Split?

Cipla has split 3 times. (See the CIPLA stock split history page for full effective split date and price information.)

How Many Employees Does Cipla Have?

Cipla has 31369 employees, based on their latest Companies House report.

What is the current trading status of Cipla (NSE: CIPLA)?

As of 07/11/2026, Cipla (CIPLA) is trading at a share price of 1,411.00 INR, with a previous close of 1,404.10 INR. The stock has fluctuated within a day range of 1,382.00 INR to 1,411.00 INR, while its 52-week range spans from 1,165.70 INR to 1,539.70 INR.

What Is Cipla (CIPLA) Price Target According to Analysts?

The average 12-month price target for Cipla is 1,507.31 INR, with a high estimate of 1800 INR and a low estimate of 1214 INR. 22 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +6.83% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.